Atrial fibrillation (AF) is the most commonly encountered arrhythmia in clinical practice. Recent advances in technology and in the understanding of the pathophysiology of AF have led to more definitive and potentially curative therapeutic approaches. In this setting, echocardiography has a unique and important role in the assessment of cardiac structure and function, risk stratification, and increasingly in guiding the management of AF. Because of its recognised value, echocardiography has become established in guidelines for management of AF and utilisation of echocardiography has increased, particularly of transoesophageal echocardiography to guide direct current cardioversion or detect cardiac sources of embolism. Even more recently the development of intracardiac echocardiography has led to real-time guidance of percutaneous interventions, including radiofrequency ablation and left atrial appendage closure procedures for patients with AF.

In this review, we highlight the echocardiographic modalities that are available and their role in the evaluation and management of AF.
to overcome this deficiency, including the use of microbubble contrast agents for better visualisation.

**Transoesophageal echocardiography**

Transoesophageal echocardiography (TOE), performed with 3–7 MHz multiplane transducers mounted on steerable modified fibroscopy probes, allows high resolution interrogation of posterior cardiac structures, including the atria, interatrial septum, and pulmonary veins. Most importantly, the atrial appendages can be visualised for thrombus. More accurate evaluation of valvar lesions, especially prosthetic dysfunction, is possible by TOE and alternative thromboembolic sources can be readily identified, including complex atheroma of the ascending thoracic aorta and arch. Although TOE is very safe, with major complications occurring in < 0.02% of procedures, it is not indicated for all patients in AF, but generally performed in patients at high risk of thromboembolism, those being considered for early cardioversion, or those with a secondary indication such as valvar disease.

**Intracardiac echocardiography**

Intracardiac echocardiography (ICE) is performed with a 6–12 MHz transducer placed in the right atrium via a 6–10 French sheath in the right femoral vein. Modified from intravascular ultrasound probes, these steerable monoplane transducers produce ultrasound waves mechanically or, like TOE, via a phased array. The latter offer the same modalities as TOE including colour, pulsed wave, and continuous wave Doppler, to allow assessment of intracardiac flow in addition to 2D visualisation of structures.

ICE can play a key role in the guidance of cardiac interventions and in some centres is used routinely for radiofrequency ablation procedures as well as recently for percutaneous closure of patent foramen ovale or atrial septal defects. The utility and cost effectiveness of ICE in these settings is still being evaluated.

Table 1 summarises the indices measured by these different echocardiographic modalities.

### Table 1  Summary of the indices measured by different echocardiographic modalities

<table>
<thead>
<tr>
<th>Modality</th>
<th>Indices measured</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transoesophageal echo</td>
<td>LA/LAA structure, function, SEC, and thrombus</td>
</tr>
<tr>
<td></td>
<td>Pulmonary vein anatomy/flows</td>
</tr>
<tr>
<td></td>
<td>Inter-atrial septum (PFO, etc)</td>
</tr>
<tr>
<td></td>
<td>Ascending aorta and arch atheroma</td>
</tr>
<tr>
<td></td>
<td>Valvar function</td>
</tr>
<tr>
<td></td>
<td>Guide therapy*</td>
</tr>
<tr>
<td>Intracardiac echo</td>
<td>LA/LAA structure and function</td>
</tr>
<tr>
<td></td>
<td>LA/LAA thrombus</td>
</tr>
<tr>
<td></td>
<td>Inter-atrial septum</td>
</tr>
<tr>
<td></td>
<td>Pulmonary vein anatomy/flows</td>
</tr>
<tr>
<td></td>
<td>Guide therapy*</td>
</tr>
</tbody>
</table>

*Radiofrequency ablation, valvoplasty, PFO/ASD closure devices, LAA occlusion device insertion.

**ECHOCARDIOGRAPHIC ASSESSMENT OF AF AETIOLOGY**

Transoesophageal echocardiography readily identifies important underlying conditions that predispose to AF, including left ventricular systolic dysfunction caused by ischaemic or dilated cardiomyopathy, left ventricular hypertrophy caused by hypertension, valvar heart disease—particularly rheumatic mitral stenosis—or pericardial disease.

A normal heart (no structural abnormality) at echocardiography is significant, particularly in young subjects, as it suggests a triggered mechanism for AF that may be amenable to radiofrequency ablation.

**ECHOCARDIOGRAPHIC ASSESSMENT OF CARDIAC STRUCTURE AND FUNCTION IN AF**

A thorough TTE should include quantification of chamber dimensions, wall thickness, left ventricular systolic and diastolic function, and valvar function. Indices such as left atrial size, left ventricular wall thickness, and left ventricular dysfunction are independent predictors for the development of AF. For assessment of diastolic function, abnormal myocardial relaxation is detectable by reduced early diastolic mitral annular (Ea) velocities from TDI or by a delayed velocity of early left ventricular flow propagation (Vp) from M-mode. The ratio of peak early transmural velocity (E) to early diastolic mitral annular (Ea) velocity (the E/Ea ratio) has been shown to reliably estimate left ventricular filling pressures in subjects in AF.

The anteroposterior left atrial dimension is measured in the parasternal long or short axis from M mode or 2D imaging, while left atrial area or volume (modified Simpson’s rule) can be measured in the apical two and four chamber views. The atria are commonly enlarged in AF and continue to dilate with persistent AF, but may diminish in size when sinus rhythm is restored. Increased left atrial volume may be a stronger predictor of incident AF than left atrial dimensions alone, while severe left atrial dilatation is associated with a low probability of successful cardioversion for chronic AF. Left atrial mechanical function is difficult to evaluate during AF, but when sinus rhythm is restored, it can be assessed with the transmitral atrial (A) wave velocity from pulsed wave Doppler and the mitral annular late diastolic (Aa) velocity from TDI. Depending on AF duration, the peak transmitral A wave velocity may be reduced for up to four weeks after successful cardioversion, due to atrial stunning.

TOE is the modality of choice for assessing the LAA and detecting left atrial and LAA thrombus (fig 1A). Modern multiplane TOE in experienced hands can detect thrombi with a sensitivity and specificity in the order of 95–100%. TOE should be used to confirm thrombus resolution before subsequent cardioversion in patients with documented thrombus. Up to 80% of left atrial thrombi have disappeared after seven weeks of anticoagulation. TOE also accurately identifies spontaneous echo contrast (SEC or “smoke”) and “sludge”. LAA smoke (fig 1B), identified as swirling echodensity in the LAA and left atrium, is a marker of stasis and a probable precursor of thrombus. Severe SEC or smoke is associated with later development of LAA thrombus and with systemic embolisation. LAA sludge (fig 1C) is viscid but not solid echodensity in the LAA without clear thrombus formation. While the distinction is arbitrary and subjective, sludge represents a stage further along the continuum towards thrombus formation and appears to have greater prognostic significance than smoke. LAA mechanical function,
including LAA emptying velocities, can be assessed from TOE using pulsed wave Doppler with a sample volume placed 1 cm into the appendage at transducer phased array angles between 45–120˚. Low LAA velocities (< 20 cm/s) correlate strongly with the presence of spontaneous echo contrast and thrombus formation, while LAA emptying velocities > 40 cm/s predict a greater likelihood of sustained sinus rhythm one year after cardioversion. The concept of LAA stunning, particularly following direct current (DC) cardioversion, is important. TOE performed immediately before and after DC cardioversion demonstrates a decline in left atrial and LAA function and increased smoke in a significant number of patients. New LAA thrombus formation has been demonstrated immediately after DC cardioversion. Stunning has been seen with spontaneous and pharmacological cardioversion as well. The severity and duration of atrial stunning appears to reflect the duration of antecedent AF.

TOE also allows more accurate assessment of pulmonary vein systolic, diastolic, and atrial reversal (in sinus rhythm) flow velocities, which is particularly relevant in patients undergoing pulmonary vein isolation procedures.

Finally, TOE allows accurate diagnosis of important associated lesions that may cause thromboembolism, in particular, complex ascending aortic and arch atheroma.

ECHOCARDIOGRAPHIC ASSESSMENT OF COMPLICATIONS AND MORTALITY IN AF

AF is an independent predictor of increased mortality in the general population. Among subjects with AF, several echocardiographic indices predict increased mortality, including presence of thrombus and left ventricular systolic dysfunction. Clinical factors such as age, prior thromboembolism, hypertension, diabetes or heart failure are strong independent predictors of stroke in AF. Several echocardiographic indices also predict thromboembolic stroke, including rheumatic mitral valve disease, left ventricular systolic dysfunction or hypertrophy on TTE, and markers of left atrial/LAA dysfunction or stasis on TOE. In the SPAF (stroke prevention in atrial fibrillation) III study the presence of a left atrial abnormality (LAA thrombi, LAA flow velocities < 20 cm/sec, or severe spontaneous echo contrast) or complex aortic atheroma at TOE was associated with a higher risk of thromboembolism. Patients with both left atrial abnormality and complex aortic atheroma had an annual incidence of embolic events in the order of 21% compared to 1.4% in the absence of these findings. In other series, the presence of a left atrial thrombus on TOE is associated with an annual risk of stroke in excess of 10% and an annual rise of death in excess of 15%. Hence, TTE and TOE findings may provide prognostic information that is additive to traditional clinical factors.

ECHOCARDIOGRAPHIC GUIDANCE OF TREATMENT IN AF

TOE guided cardioversion

DC cardioversion for AF offers the opportunity to restore sinus rhythm, optimise cardiac performance, and potentially reduce the risk of thromboembolic events and bleeding complications caused by prolonged anticoagulation. To avoid thromboembolic events (~5% in non-anticoagulated patients) around the time of cardioversion, patients with AF of more than 48 hours’ duration have traditionally been anticoagulated for at least seven weeks—three weeks before and four weeks after the procedure. With this approach, thromboembolic complications (< 1%) and major bleeding (1–2%) are infrequent. The procedure is initially successful in up to 86% of subjects with sinus rhythm maintained in up to 50% at one year. Predictors of successful cardioversion include age, duration of AF, underlying aetiology, and technical factors. Additionally, severe left atrial dilatation and left ventricular systolic dysfunction on echocardiography predict a lower likelihood of success.

Echocardiographic predictors of thromboembolism in AF

- Valve disease
- Left ventricular systolic dysfunction
- Left atrial dilatation
- *Complex aortic atheroma
- *Left atrial appendage thrombus > sludge > smoke
- *Reduced LAA velocities (< 20 cm/s)

*Identified at TOE
While the long term value of DC cardioversion has been brought into question by the recent findings of the AFFIRM (atrial fibrillation follow-up investigation of rhythm management) study, it is clear that symptomatic patients and a proportion of those who are asymptomatic will continue to receive benefit from this treatment.

For some time, TOE has been used before cardioversion in patients presenting with AF of more than 48 hours’ duration. TOE potentially facilitates early cardioversion without prolonged anticoagulation in low risk patients needing semi-urgent cardioversion or for whom the risk of anticoagulation is high. TOE also identifies high risk patients with thrombus in whom DC cardioversion should be postponed.

The routine use of TOE guided DC cardioversion with short term anticoagulation has potential advantages over the conventional approach; these include the possibility of reduced embolic events due to recognition of LAA thrombi at TOE, shorter period of anticoagulation with less bleeding complications, higher rates of conversion to and maintenance of sinus rhythm due to prompt cardioversion, and less opportunity for atrial remodelling or stunning. The TOE guided strategy appears to be economically equivalent to the conventional approach.

A TOE guided approach to DC cardioversion does not obviate the need for therapeutic anticoagulation. Patients receiving short term therapeutic anticoagulation, and in whom thrombus had been excluded by TOE, experience low rates of embolism (< 1%)—comparable to rates in subjects receiving three weeks of anticoagulation following DC cardioversion from AF. Thromboembolic events have been documented following cardioversion from AF among patients with absent or subtherapeutic anticoagulation despite a negative TOE for thrombus, possibly caused by tiny thrombi not seen at TOE or as a result of thrombus formation caused by LAA stunning following cardioversion. Therefore, all patients should be adequately anticoagulated during and after cardioversion even when there is no LAA thrombus or the duration of AF is brief.

The ACUTE (assessment of cardioversion using transoesophageal echocardiography) multi-centre study compared a TOE guided strategy with short term anticoagulation to a conventional anticoagulation strategy in patients undergoing DC cardioversion for AF of > 2 days’ duration. The primary end point events were ischaemic stroke, TIA, and systemic embolisation during an eight week period from enrolment. Six hundred and nineteen patients were randomised to the TOE guided arm with 603 assigned to the conventional arm. Of the 619 patients in the TOE guided group, 425 (69%) had early DC cardioversion at a mean of three days; and in 344 (81%) of these, the cardioversion was successful. Among the 124 patients who had TOE but not early DC cardioversion (20%), cardioversion was postponed in 76 patients (61%) due to the finding of thrombi. These 76 patients (13.8%) were identified among the 549 who actually had the TOE exam. In the TOE guided group, there were five embolic events of which two patients experienced embolic events within the first week after cardioversion, associated with recurrence of AF and subtherapeutic anticoagulation.

Of the 603 in the conventional group, 333 (55%) underwent DC cardioversion at a mean of 31 days; and in 266 (80%) cardioversion was immediately successful. Of the 270 (45%) who did not undergo cardioversion, 47% reverted to sinus rhythm spontaneously or with pharmacologic conversion. The remaining 53% of patients did not undergo cardioversion within the eight week period due to patient indications for echocardiography

- Assessment of cardiac structure and function
- Assessment of aetiology of AF
- Assessment of thromboembolic risk or the aetiology of peripheral embolism
- TOE guided DC cardioversion/stratification for anticoagulation
- TOE guidance of percutaneous or surgical LAA closure
- ICE guided RF ablation procedures

Figure 2 Images acquired from intracardiac echocardiography (ICE). (A) Transeptal puncture with catheter (arrow) passing from right atrium to left atrium. (B) Colour flow mapping showing the confluence of the left upper and lower pulmonary veins (LUPV and LLPV). (C) Pulsed wave Doppler of the LAA showing preservation of velocities in a patient with AF. (D) Pulsed Doppler of the LUPV showing blunting of systolic (S) flow compared to diastolic (D) flow and a narrow atrial systolic reversal (AR) following cardioversion in the same patient.
refusal, death, surgery, physician decision, subtherapeutic anticoagulation, bleeding or loss to follow up. In the conventional group, there were three embolic events of which one patient experienced an embolic event within the first week after cardioversion. Thirty two patients (5%) crossed over to the TOE arm due to haemodynamic instability (hypotension or heart failure). There was no difference in the primary composite end point of stroke, TIA, and peripheral embolism between the TOE guided arm and conventional arms (0.81% v 0.50%; p = 0.50). However, the composite of major and minor bleeding occurred significantly less frequently in the TOE guided than the conventional arm (3.1% v 5.5%; p = 0.023). There was no significant difference between the two groups in the rate of death from cardiac causes and non-cardiac causes, but there was a trend for a higher rate of death in the TOE guided group (2.4% v 1.0%; p = 0.06).

**Figure 3** Stenosis of the left upper pulmonary vein (LUPV) following radiofrequency ablation for AF. (A) Narrowing of the LUPV ostium (arrow) on multi-detector computed tomography. (B) Colour Doppler image from TOE demonstrating aliasing of flow in the LUPV. (C) Pulsed wave Doppler of the LUPV demonstrating phasic systolic (S) and diastolic (D) flow with increased velocities (> 1.5 m/s).

**Figure 4** Percutaneous closure of the LAA. (A) Occluder device. (B) Fluoroscopic image of the occluder device in situ. (C) ICE image of the left atrium (LA) and LAA before deployment. (D) ICE following deployment of the device. Adapted and reproduced from Nakai et al., with permission.
Maintenance of sinus rhythm at eight week follow up was similar in the two groups (53% vs 50%; p = 0.43).

In summary, the ACUTE study found that embolic events and maintenance of sinus rhythm were similar in the two treatment strategies, although major and minor bleeding was lower with the TOE guided strategy. These findings suggest that a TOE guided approach to DC cardioversion using short term anticoagulation is a safe and clinically effective alternative to the conventional strategy. The ACUTE II study will test whether low molecular weight heparin can be substituted for unfractionated heparin in this setting.

In patients presenting with a shorter duration of AF (≤ 48 hours) the risk of thromboembolism following cardioversion is low. While anticoagulation before cardioversion is recommended in these patients, TOE is not usually mandated unless patients are at high risk for thromboembolism. LAA thrombi may be present in up to 20% of patients presenting with new onset (≤ 72 hours) AF and a history of prior thromboembolism.

LAA dysfunction or stunning after cardioversion and LAA smoke or thrombus can be seen in atrial flutter. For this reason, a similar approach to cardioversion is generally taken for patients with atrial flutter.

In our practice (fig 5), we recommend TOE guided DC cardioversion for patients with new onset AF (≤ 48 hours) in three main circumstances: (1) for patients who require expedited (but not emergency) cardioversion because of significant symptoms, heart failure, angina, or haemodynamic instability; (2) patients with suboptimal anticoagulation or who cannot take anticoagulants because of a high risk of bleeding; and (3) patients at significant risk of left atrial/ LAA thrombus or stroke (see above). We also perform TOE...
guided DC cardioversion in a significant proportion of patients without these indications—particularly hospital inpatients—for whom expedited cardioversion is preferred.

**Radiofrequency ablation**

Radiofrequency ablation is suitable in a significant number of patients in whom AF is caused by foci in the pulmonary veins.1 Increasingly, ICE is being used to guide RF ablation procedures.23 Continuous imaging with ICE can be performed by the operator or an assistant and provides excellent visualisation of the atria and appendages, inter-atrial septum, and pulmonary veins. ICE facilitates trans-septal puncture, guide placement, and optimal tissue contact of mapping and ablation catheters, and allows identification of coagulum on the ablation catheter. ICE also allows detection of micro-bubbles at the ablation site, which may potentially guide optimal catheter placement and energy delivery.20 In addition, ICE facilitates instant recognition of significant complications such as pericardial effusion or tamponade, aortic puncture during trans-septal puncture, and may actually reduce the frequency of these complications. The use of ICE during radiofrequency ablation of the pulmonary vein ostia at our institution has been associated with shorter fluoroscopy and total procedure times, less energy use, higher success rates, and fewer complications including pulmonary vein stenosis (A Natale, personal communication). Figure 2 shows images acquired from ICE.

In the absence of ICE, TOE has an important role before ablation in assessing the left atrium and LAA for thrombus, the inter-atrial septum for patient foramen ovale (PFO), and for documenting baseline pulmonary vein flow profiles. TOE examination following catheter ablation of the pulmonary veins has documented asymptomatic increases in peak systolic flow velocities measured by Doppler in up to 40% of patients. Symptomatic pulmonary vein stenosis has been documented but is uncommon and may manifest as cough, dyspnoea, pulmonary hypertension, pulmonary oedema isolated to a single lobe, or with abnormal ventilation or perfusion lung scans in the absence of thromboembolism.21 With TOE, the pulmonary vein ostia can be visualised for evidence of stenosis; more importantly, the physiological significance of any narrowing can be assessed with colour flow mapping and pulsed or continuous wave Doppler of pulmonary vein flows (fig 3).

**Surgical procedures**

The surgical MAZE III procedure—involving excision or ligation of the appendages, isolation of the pulmonary veins and creation of incisions in the LA to reduce multiple re-entry circuits—abolishes AF in a significant number of patients. Due to the complexity of the operation, time on cardiopulmonary bypass, and bleeding risk, the latest evolution is to isolate the pulmonary veins and create lines of conduction block in the left atrium. This technique using heat based energy sources (radiofrequency) or cryotherapy is quicker and associated with fewer complications. TOE has an important role in assessing the atria and appendages for thrombus before the MAZE III procedure. Doppler echocardiography can also be used to track changes in atrial function or the presence of LAA communication with the left atrial cavity after the procedure.

Increasingly, LAA ligation is being undertaken at the time of cardiac surgery in patients at higher risk for AF or thromboembolism. Doppler imaging with intraoperative TOE allows immediate assessment of the efficacy of ligation at the time of surgery. We have seen a number of cases where the initial ligation was not adequate and communication between the LAA and left atrial cavity was detected.

**Percutaneous closure of the left atrial appendage**

Percutaneous occlusion of the left atrial appendage by an expandable occluder device is a new experimental approach (fig 4).22 Because 90% of thrombi occur in the LA appendage, occlusion of the LAA could potentially reduce the rate of thromboembolic complications in high risk patients or those who cannot be safely anticoagulated long term. In a canine model, insertion of the device was facilitated by ICE, which allowed optimal positioning of the device. Colour flow mapping was used to determine the optimal fit of the device and any significant residual flow out of the appendage (fig 4).22 TOE was used in a recent clinical study to guide placement and assess outcome and complications such as thrombus formation around the device.23

While further studies will be necessary to determine the role of this device in the treatment of AF, echocardiography is likely to play an important role in this validation process and is ideally suited to determining appropriate patients, guiding insertion of the device, and tracking potential complications.

**CONCLUSIONS**

Echocardiography provides vital information about cardiac function, complications, and prognosis in patients with AF. Modalities like TOE and ICE can help to guide ablation therapy and decisions related to cardioversion. The integrated use of echocardiography will be an important component in the optimal management of the looming AF epidemic.

**ACKNOWLEDGEMENTS**

The authors wish to acknowledge Marie Campbell for assistance in the preparation and review of the manuscript.

**Authors’ affiliations**

R Troughton, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand

C R Asher, A L Klein, Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Cleveland, Ohio, USA

Conflict of interest statement: Dr Klein has a research grant from Aventis. There are no financial or personal associations that may pose a conflict of interest in connection with the submitted article for any of the other authors to disclose.

**REFERENCES**


A comprehensive recent review of the role of TOE guided cardioversion for AF.
The role of echocardiography in atrial fibrillation and cardioversion

Richard W Troughton, Craig R Asher and Allan L Klein

*Heart* 2003 89: 1447-1454
doi: 10.1136/heart.89.12.1447

Updated information and services can be found at:
[http://heart.bmj.com/content/89/12/1447](http://heart.bmj.com/content/89/12/1447)

These include:

**References**
This article cites 23 articles, 8 of which you can access for free at:
[http://heart.bmj.com/content/89/12/1447#BIBL](http://heart.bmj.com/content/89/12/1447#BIBL)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
- Clinical diagnostic tests (4778)
- Echocardiography (2126)
- Drugs: cardiovascular system (8839)
- Epidemiology (3776)
- Hypertension (3004)
- Education in Heart (554)

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)